Alnylam Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | ALNY

Alnylam Pharmaceuticals total non-operating income/expense for the twelve months ending June 30, 2024 was $-0.164B, a 29.54% decline year-over-year.

  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2023 was $-0.151B, a 55.74% decline from 2022.
  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2022 was $-0.342B, a 138.29% increase from 2021.
  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2021 was $-0.143B, a 428.28% increase from 2020.

Alnylam Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | ALNY

  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2023 was $-0.151B, a 55.74% decline from 2022.
  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2022 was $-0.342B, a 138.29% increase from 2021.
  • Alnylam Pharmaceuticals annual total non-operating income/expense for 2021 was $-0.143B, a 428.28% increase from 2020.